Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 227 | 2024 | 17275 | 12.510 |
Why?
|
Growth Hormone-Releasing Hormone | 30 | 2024 | 128 | 9.740 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 36 | 2021 | 138 | 7.540 |
Why?
|
Plaque, Atherosclerotic | 25 | 2024 | 1505 | 4.660 |
Why?
|
Human Growth Hormone | 27 | 2014 | 638 | 4.480 |
Why?
|
Body Composition | 76 | 2019 | 2416 | 4.050 |
Why?
|
Intra-Abdominal Fat | 20 | 2023 | 608 | 3.640 |
Why?
|
Cardiovascular Diseases | 55 | 2024 | 15396 | 3.560 |
Why?
|
HIV | 24 | 2023 | 1581 | 3.440 |
Why?
|
Adipose Tissue | 50 | 2024 | 3299 | 3.200 |
Why?
|
Coronary Artery Disease | 30 | 2024 | 6363 | 3.200 |
Why?
|
HIV Wasting Syndrome | 21 | 2005 | 97 | 3.070 |
Why?
|
Adiposity | 19 | 2024 | 1858 | 3.040 |
Why?
|
Arteritis | 8 | 2024 | 159 | 2.940 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 16 | 2024 | 3227 | 2.920 |
Why?
|
Lipodystrophy | 17 | 2022 | 148 | 2.870 |
Why?
|
Quinolines | 11 | 2024 | 759 | 2.690 |
Why?
|
Insulin Resistance | 38 | 2022 | 3941 | 2.610 |
Why?
|
Atherosclerosis | 18 | 2024 | 3401 | 2.600 |
Why?
|
Insulin-Like Growth Factor I | 34 | 2021 | 1927 | 2.350 |
Why?
|
Testosterone | 29 | 2011 | 2471 | 2.230 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 10 | 2019 | 282 | 2.120 |
Why?
|
Subcutaneous Fat | 8 | 2021 | 393 | 2.030 |
Why?
|
Anti-HIV Agents | 36 | 2020 | 4504 | 2.020 |
Why?
|
Obesity | 32 | 2024 | 12870 | 1.870 |
Why?
|
Growth Hormone | 10 | 2020 | 568 | 1.840 |
Why?
|
Renin-Angiotensin System | 7 | 2022 | 733 | 1.700 |
Why?
|
Phosphocreatine | 7 | 2013 | 261 | 1.630 |
Why?
|
Macrophage Activation | 5 | 2018 | 552 | 1.580 |
Why?
|
Inflammation | 23 | 2024 | 10719 | 1.570 |
Why?
|
Middle Aged | 194 | 2024 | 219560 | 1.450 |
Why?
|
Anti-Retroviral Agents | 19 | 2023 | 1780 | 1.440 |
Why?
|
Antiretroviral Therapy, Highly Active | 21 | 2020 | 1895 | 1.370 |
Why?
|
Adult | 213 | 2024 | 219916 | 1.310 |
Why?
|
Double-Blind Method | 38 | 2024 | 12262 | 1.300 |
Why?
|
Fatty Acids, Nonesterified | 9 | 2015 | 392 | 1.300 |
Why?
|
Receptors, Cell Surface | 11 | 2019 | 2825 | 1.280 |
Why?
|
Lipid Metabolism | 13 | 2019 | 1894 | 1.280 |
Why?
|
Fats | 4 | 2019 | 99 | 1.280 |
Why?
|
Humans | 361 | 2024 | 758381 | 1.270 |
Why?
|
Male | 227 | 2024 | 358742 | 1.250 |
Why?
|
Androgens | 11 | 2009 | 1291 | 1.240 |
Why?
|
Tunica Media | 5 | 2013 | 112 | 1.180 |
Why?
|
Blood Proteins | 4 | 2023 | 1173 | 1.180 |
Why?
|
Muscle, Skeletal | 17 | 2023 | 4902 | 1.180 |
Why?
|
Ribonuclease III | 4 | 2021 | 279 | 1.170 |
Why?
|
Adipose Tissue, Brown | 5 | 2019 | 755 | 1.160 |
Why?
|
Blood Glucose | 30 | 2021 | 6347 | 1.150 |
Why?
|
Metformin | 7 | 2014 | 907 | 1.150 |
Why?
|
Anorexia Nervosa | 18 | 2006 | 1361 | 1.140 |
Why?
|
Placebos | 16 | 2024 | 1661 | 1.140 |
Why?
|
Female | 235 | 2024 | 390316 | 1.140 |
Why?
|
Thiazolidinediones | 6 | 2010 | 460 | 1.140 |
Why?
|
Antigens, CD | 10 | 2019 | 3997 | 1.120 |
Why?
|
Proteomics | 7 | 2023 | 3816 | 1.110 |
Why?
|
Carotid Arteries | 7 | 2017 | 939 | 1.100 |
Why?
|
CD4 Lymphocyte Count | 25 | 2020 | 2569 | 1.070 |
Why?
|
DEAD-box RNA Helicases | 3 | 2021 | 383 | 1.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 5 | 2010 | 584 | 1.070 |
Why?
|
Absorptiometry, Photon | 25 | 2024 | 1735 | 1.030 |
Why?
|
Tunica Intima | 5 | 2013 | 459 | 1.020 |
Why?
|
Bone Density | 23 | 2009 | 3533 | 1.010 |
Why?
|
Lipids | 20 | 2018 | 3326 | 0.990 |
Why?
|
Aldosterone | 5 | 2022 | 866 | 0.980 |
Why?
|
Abdominal Fat | 6 | 2014 | 221 | 0.970 |
Why?
|
HIV Integrase Inhibitors | 3 | 2024 | 165 | 0.950 |
Why?
|
Hyperinsulinism | 8 | 2017 | 400 | 0.940 |
Why?
|
Monocytes | 7 | 2021 | 2570 | 0.940 |
Why?
|
Hypertriglyceridemia | 3 | 2022 | 293 | 0.920 |
Why?
|
Hypoglycemic Agents | 11 | 2012 | 3069 | 0.910 |
Why?
|
HIV Protease Inhibitors | 10 | 2019 | 432 | 0.900 |
Why?
|
Bone Diseases, Metabolic | 10 | 2005 | 409 | 0.890 |
Why?
|
Fatty Liver | 4 | 2018 | 777 | 0.880 |
Why?
|
Peptide Hormones | 4 | 2005 | 132 | 0.880 |
Why?
|
Leptin | 14 | 2022 | 1591 | 0.870 |
Why?
|
Fluorodeoxyglucose F18 | 10 | 2024 | 2004 | 0.870 |
Why?
|
Insulin | 23 | 2018 | 6578 | 0.860 |
Why?
|
Lipoproteins, HDL | 5 | 2014 | 664 | 0.860 |
Why?
|
HIV-1 | 12 | 2023 | 6850 | 0.850 |
Why?
|
Pyrazines | 5 | 2015 | 1198 | 0.850 |
Why?
|
Body Mass Index | 39 | 2023 | 12876 | 0.850 |
Why?
|
Viral Load | 17 | 2022 | 3321 | 0.830 |
Why?
|
Hypolipidemic Agents | 6 | 2015 | 609 | 0.830 |
Why?
|
Risk Factors | 64 | 2024 | 73806 | 0.830 |
Why?
|
Adiponectin | 11 | 2011 | 1114 | 0.800 |
Why?
|
HIV Integrase | 1 | 2023 | 121 | 0.800 |
Why?
|
Lipoproteins, LDL | 7 | 2024 | 640 | 0.790 |
Why?
|
Body Weight | 20 | 2023 | 4603 | 0.780 |
Why?
|
Coronary Angiography | 15 | 2024 | 4451 | 0.770 |
Why?
|
Metabolic Diseases | 5 | 2014 | 682 | 0.770 |
Why?
|
Ethinyl Estradiol | 5 | 2005 | 114 | 0.740 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 3 | 2021 | 206 | 0.740 |
Why?
|
Subcutaneous Fat, Abdominal | 2 | 2019 | 91 | 0.720 |
Why?
|
Obesity, Abdominal | 5 | 2019 | 374 | 0.700 |
Why?
|
Carotid Artery Diseases | 3 | 2017 | 872 | 0.690 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10146 | 0.690 |
Why?
|
Spironolactone | 1 | 2023 | 410 | 0.680 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 831 | 0.680 |
Why?
|
Liver | 8 | 2023 | 7502 | 0.680 |
Why?
|
Immunoglobulin G | 6 | 2024 | 4540 | 0.660 |
Why?
|
Hypogonadism | 9 | 2005 | 800 | 0.660 |
Why?
|
Proteome | 2 | 2020 | 1855 | 0.650 |
Why?
|
Regression Analysis | 23 | 2018 | 6353 | 0.650 |
Why?
|
Glucose | 11 | 2012 | 4336 | 0.650 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2019 | 34 | 0.650 |
Why?
|
Adolescent | 68 | 2021 | 87888 | 0.640 |
Why?
|
Growth Substances | 1 | 2021 | 768 | 0.640 |
Why?
|
Hypothalamic Diseases | 6 | 2011 | 134 | 0.640 |
Why?
|
Acquired Immunodeficiency Syndrome | 7 | 2012 | 2197 | 0.640 |
Why?
|
Calcinosis | 3 | 2012 | 1467 | 0.610 |
Why?
|
Aspartate Aminotransferases | 3 | 2017 | 415 | 0.610 |
Why?
|
Primary Prevention | 5 | 2023 | 1185 | 0.600 |
Why?
|
Amenorrhea | 8 | 2011 | 480 | 0.590 |
Why?
|
Life Style | 5 | 2014 | 3886 | 0.580 |
Why?
|
Adrenal Glands | 4 | 2010 | 554 | 0.580 |
Why?
|
Hormones | 8 | 2015 | 869 | 0.570 |
Why?
|
Anticholesteremic Agents | 4 | 2018 | 963 | 0.550 |
Why?
|
Young Adult | 37 | 2021 | 58808 | 0.550 |
Why?
|
Case-Control Studies | 27 | 2022 | 22031 | 0.540 |
Why?
|
Alanine Transaminase | 2 | 2017 | 604 | 0.530 |
Why?
|
Amino Acids | 3 | 2020 | 1713 | 0.530 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 851 | 0.530 |
Why?
|
Mitochondria, Muscle | 4 | 2011 | 172 | 0.520 |
Why?
|
Exercise | 13 | 2013 | 5788 | 0.510 |
Why?
|
Dyslipidemias | 5 | 2011 | 868 | 0.510 |
Why?
|
Immunologic Factors | 3 | 2017 | 1585 | 0.500 |
Why?
|
Hot Flashes | 2 | 2018 | 328 | 0.500 |
Why?
|
Food Deprivation | 2 | 2005 | 114 | 0.500 |
Why?
|
Macrophages | 4 | 2024 | 5737 | 0.490 |
Why?
|
Pravastatin | 1 | 2017 | 392 | 0.490 |
Why?
|
Norethindrone | 3 | 2004 | 56 | 0.480 |
Why?
|
Fasting | 10 | 2012 | 1599 | 0.480 |
Why?
|
Stavudine | 4 | 2007 | 84 | 0.480 |
Why?
|
Triglycerides | 11 | 2020 | 2450 | 0.480 |
Why?
|
Protease Inhibitors | 5 | 2006 | 754 | 0.480 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2011 | 4342 | 0.470 |
Why?
|
Anti-Obesity Agents | 1 | 2017 | 227 | 0.460 |
Why?
|
Waist-Hip Ratio | 4 | 2008 | 516 | 0.450 |
Why?
|
Adipose Tissue, White | 2 | 2017 | 365 | 0.450 |
Why?
|
Tomography, X-Ray Computed | 18 | 2019 | 20500 | 0.440 |
Why?
|
Arginine | 6 | 2010 | 933 | 0.440 |
Why?
|
Heart Diseases | 3 | 2019 | 2782 | 0.440 |
Why?
|
Bone Remodeling | 5 | 2004 | 579 | 0.430 |
Why?
|
Fibroblast Growth Factors | 3 | 2017 | 867 | 0.430 |
Why?
|
Positron-Emission Tomography | 7 | 2016 | 6457 | 0.430 |
Why?
|
Reverse Transcriptase Inhibitors | 4 | 2022 | 619 | 0.430 |
Why?
|
Nutritional Status | 11 | 2011 | 1607 | 0.430 |
Why?
|
Cholesterol | 7 | 2017 | 2901 | 0.430 |
Why?
|
C-Reactive Protein | 6 | 2011 | 3812 | 0.430 |
Why?
|
Treatment Outcome | 31 | 2024 | 64379 | 0.430 |
Why?
|
Weight Loss | 7 | 2003 | 2671 | 0.430 |
Why?
|
Risk Reduction Behavior | 4 | 2019 | 1098 | 0.430 |
Why?
|
Hyperlipidemias | 4 | 2011 | 771 | 0.420 |
Why?
|
Sodium | 3 | 2022 | 1588 | 0.420 |
Why?
|
Fibrosis | 2 | 2018 | 2038 | 0.420 |
Why?
|
Adipogenesis | 4 | 2021 | 358 | 0.420 |
Why?
|
Cross-Sectional Studies | 28 | 2023 | 25953 | 0.410 |
Why?
|
Gene Expression | 3 | 2020 | 7583 | 0.410 |
Why?
|
Coronary Vessels | 5 | 2023 | 3072 | 0.410 |
Why?
|
Menopause | 3 | 2020 | 1639 | 0.410 |
Why?
|
Energy Metabolism | 13 | 2016 | 2868 | 0.390 |
Why?
|
Hypopituitarism | 1 | 2013 | 250 | 0.390 |
Why?
|
Lymphocyte Activation | 2 | 2012 | 5490 | 0.390 |
Why?
|
Lipolysis | 2 | 2003 | 209 | 0.380 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2003 | 116 | 0.380 |
Why?
|
Inflammation Mediators | 2 | 2018 | 1878 | 0.380 |
Why?
|
Aged | 45 | 2023 | 168217 | 0.380 |
Why?
|
Adipocytes, White | 2 | 2014 | 91 | 0.380 |
Why?
|
Muscles | 5 | 2024 | 1579 | 0.380 |
Why?
|
Magnetic Resonance Spectroscopy | 9 | 2020 | 3758 | 0.370 |
Why?
|
Endocrine Glands | 3 | 2015 | 101 | 0.370 |
Why?
|
Energy Intake | 10 | 2012 | 2127 | 0.370 |
Why?
|
Cardiovascular System | 1 | 2018 | 835 | 0.370 |
Why?
|
Nutrition Disorders | 1 | 2011 | 205 | 0.370 |
Why?
|
Fibronectins | 1 | 2014 | 722 | 0.370 |
Why?
|
Diet, Sodium-Restricted | 3 | 2018 | 291 | 0.360 |
Why?
|
American Heart Association | 4 | 2019 | 1039 | 0.360 |
Why?
|
Neck | 2 | 2016 | 731 | 0.360 |
Why?
|
Sulfotransferases | 1 | 2011 | 149 | 0.360 |
Why?
|
Cardiomyopathies | 2 | 2020 | 1944 | 0.360 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 173 | 0.350 |
Why?
|
Immunity | 3 | 2024 | 998 | 0.350 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2011 | 278 | 0.350 |
Why?
|
Intestinal Diseases | 1 | 2015 | 505 | 0.350 |
Why?
|
Iodide Peroxidase | 1 | 2012 | 294 | 0.350 |
Why?
|
Muscle Weakness | 2 | 2023 | 413 | 0.340 |
Why?
|
Hydrocortisone | 9 | 2010 | 1802 | 0.340 |
Why?
|
Gonadotropins | 2 | 2009 | 241 | 0.340 |
Why?
|
Glucose Clamp Technique | 4 | 2018 | 263 | 0.340 |
Why?
|
Multivariate Analysis | 15 | 2017 | 12096 | 0.340 |
Why?
|
Adipokines | 2 | 2017 | 311 | 0.340 |
Why?
|
Pericardium | 1 | 2014 | 674 | 0.340 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 5 | 2009 | 415 | 0.340 |
Why?
|
Vaccination | 1 | 2022 | 3356 | 0.340 |
Why?
|
MicroRNAs | 3 | 2021 | 3783 | 0.340 |
Why?
|
Exercise Therapy | 3 | 2011 | 919 | 0.330 |
Why?
|
Prevalence | 15 | 2022 | 15646 | 0.330 |
Why?
|
Endocrine System Diseases | 3 | 1998 | 249 | 0.330 |
Why?
|
Retinol-Binding Proteins | 1 | 2009 | 67 | 0.330 |
Why?
|
Cholesterol, HDL | 7 | 2018 | 1808 | 0.320 |
Why?
|
Multicenter Studies as Topic | 4 | 2020 | 1705 | 0.320 |
Why?
|
Weight Gain | 10 | 2023 | 2346 | 0.320 |
Why?
|
Minority Groups | 5 | 2023 | 1206 | 0.320 |
Why?
|
Up-Regulation | 2 | 2023 | 4114 | 0.320 |
Why?
|
Myocardial Infarction | 6 | 2024 | 11424 | 0.320 |
Why?
|
Glucose Tolerance Test | 8 | 2017 | 1172 | 0.320 |
Why?
|
Aorta | 2 | 2017 | 2037 | 0.320 |
Why?
|
Myocardium | 1 | 2021 | 4690 | 0.320 |
Why?
|
Estrogens | 5 | 2003 | 1520 | 0.310 |
Why?
|
Carotid Artery, Common | 2 | 2006 | 175 | 0.310 |
Why?
|
Menstruation | 7 | 2006 | 307 | 0.310 |
Why?
|
Intercellular Signaling Peptides and Proteins | 3 | 2004 | 1651 | 0.310 |
Why?
|
Cholesterol, LDL | 5 | 2024 | 2374 | 0.310 |
Why?
|
Coronary Disease | 3 | 2016 | 5917 | 0.310 |
Why?
|
Research Subjects | 2 | 2020 | 249 | 0.310 |
Why?
|
Anti-Inflammatory Agents | 1 | 2018 | 1793 | 0.300 |
Why?
|
E-Selectin | 1 | 2010 | 576 | 0.300 |
Why?
|
Fingers | 1 | 2011 | 506 | 0.300 |
Why?
|
Longitudinal Studies | 18 | 2023 | 14481 | 0.300 |
Why?
|
Bone Diseases | 1 | 2011 | 419 | 0.300 |
Why?
|
Pituitary Gland | 1 | 2010 | 637 | 0.290 |
Why?
|
Bone Marrow | 3 | 2019 | 2909 | 0.290 |
Why?
|
Norgestrel | 2 | 2005 | 11 | 0.290 |
Why?
|
Extremities | 2 | 2012 | 865 | 0.290 |
Why?
|
Proteins | 7 | 2004 | 6026 | 0.290 |
Why?
|
Cushing Syndrome | 4 | 2007 | 241 | 0.290 |
Why?
|
Feeding Behavior | 4 | 2023 | 3183 | 0.280 |
Why?
|
Anthropometry | 7 | 2009 | 1347 | 0.280 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1930 | 0.280 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 1 | 2007 | 63 | 0.280 |
Why?
|
Myocardial Ischemia | 1 | 2017 | 2108 | 0.280 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2021 | 1153 | 0.280 |
Why?
|
Waist Circumference | 3 | 2019 | 922 | 0.280 |
Why?
|
Body Fat Distribution | 4 | 2016 | 243 | 0.270 |
Why?
|
Down-Regulation | 4 | 2021 | 2905 | 0.270 |
Why?
|
Weight Lifting | 2 | 2004 | 126 | 0.270 |
Why?
|
Metyrapone | 1 | 2005 | 22 | 0.270 |
Why?
|
Steroid 11-beta-Hydroxylase | 1 | 2005 | 20 | 0.260 |
Why?
|
Adipocytes | 3 | 2021 | 1177 | 0.260 |
Why?
|
RNA, Messenger | 3 | 2019 | 12760 | 0.260 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 127 | 0.250 |
Why?
|
Diabetes Mellitus, Lipoatrophic | 1 | 2005 | 9 | 0.250 |
Why?
|
Dura Mater | 1 | 2007 | 290 | 0.250 |
Why?
|
United States | 20 | 2023 | 72140 | 0.250 |
Why?
|
Oxidative Phosphorylation | 3 | 2020 | 495 | 0.250 |
Why?
|
Aging | 6 | 2020 | 8651 | 0.250 |
Why?
|
Hormones, Ectopic | 1 | 2005 | 37 | 0.250 |
Why?
|
Lumbar Vertebrae | 7 | 2006 | 1868 | 0.250 |
Why?
|
Chemokine CCL2 | 4 | 2017 | 604 | 0.250 |
Why?
|
Perimenopause | 2 | 2018 | 141 | 0.250 |
Why?
|
Reference Values | 9 | 2009 | 4919 | 0.240 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3217 | 0.240 |
Why?
|
Asymptomatic Diseases | 4 | 2019 | 584 | 0.240 |
Why?
|
Prospective Studies | 19 | 2022 | 54136 | 0.240 |
Why?
|
Sex Factors | 9 | 2024 | 10505 | 0.240 |
Why?
|
Methylamines | 2 | 2016 | 137 | 0.240 |
Why?
|
Faculty, Medical | 2 | 2023 | 1192 | 0.240 |
Why?
|
Smoking | 5 | 2016 | 9042 | 0.240 |
Why?
|
Heart | 1 | 2017 | 4382 | 0.230 |
Why?
|
Back | 2 | 2016 | 64 | 0.230 |
Why?
|
Osteoporosis | 7 | 2007 | 1599 | 0.230 |
Why?
|
Sex Characteristics | 6 | 2023 | 2621 | 0.230 |
Why?
|
Overweight | 2 | 2018 | 2410 | 0.230 |
Why?
|
Angiotensin II | 2 | 2018 | 848 | 0.220 |
Why?
|
Disease Management | 4 | 2019 | 2500 | 0.220 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3142 | 0.220 |
Why?
|
Area Under Curve | 5 | 2010 | 1632 | 0.210 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2003 | 68 | 0.210 |
Why?
|
Risk Assessment | 12 | 2024 | 23883 | 0.210 |
Why?
|
Psoas Muscles | 1 | 2003 | 66 | 0.210 |
Why?
|
Nelfinavir | 3 | 2007 | 68 | 0.210 |
Why?
|
Adenoma | 3 | 2013 | 2148 | 0.210 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2024 | 163 | 0.210 |
Why?
|
Blood Pressure | 7 | 2018 | 8453 | 0.210 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 855 | 0.210 |
Why?
|
Hypothalamo-Hypophyseal System | 4 | 2004 | 700 | 0.210 |
Why?
|
Ghrelin | 4 | 2005 | 251 | 0.210 |
Why?
|
Appetite Stimulants | 2 | 1999 | 14 | 0.210 |
Why?
|
Caloric Restriction | 1 | 2004 | 296 | 0.200 |
Why?
|
Analysis of Variance | 6 | 2011 | 6233 | 0.200 |
Why?
|
Calorimetry, Indirect | 3 | 2009 | 174 | 0.200 |
Why?
|
Platelet Aggregation | 1 | 2005 | 773 | 0.200 |
Why?
|
Resistin | 3 | 2008 | 172 | 0.200 |
Why?
|
CCN Intercellular Signaling Proteins | 1 | 2021 | 24 | 0.200 |
Why?
|
Latent TGF-beta Binding Proteins | 1 | 2021 | 43 | 0.200 |
Why?
|
Cytomegalovirus | 2 | 2024 | 755 | 0.200 |
Why?
|
Platelet Activation | 1 | 2005 | 645 | 0.200 |
Why?
|
Periodicity | 1 | 2003 | 348 | 0.190 |
Why?
|
Cytokines | 4 | 2019 | 7338 | 0.190 |
Why?
|
Somatostatin | 1 | 2003 | 447 | 0.190 |
Why?
|
Nutritional Sciences | 1 | 2023 | 143 | 0.190 |
Why?
|
Nutrition Assessment | 2 | 2004 | 726 | 0.190 |
Why?
|
Cohort Studies | 17 | 2021 | 41252 | 0.190 |
Why?
|
Bone Resorption | 5 | 2012 | 720 | 0.190 |
Why?
|
Potassium Radioisotopes | 1 | 2000 | 12 | 0.190 |
Why?
|
Endothelium, Vascular | 2 | 2011 | 4429 | 0.190 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2154 | 0.190 |
Why?
|
Angiography | 3 | 2016 | 1599 | 0.190 |
Why?
|
Recombinant Proteins | 7 | 2008 | 6520 | 0.190 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2005 | 376 | 0.180 |
Why?
|
Eating | 2 | 2023 | 1536 | 0.180 |
Why?
|
Noise, Transportation | 1 | 2021 | 51 | 0.180 |
Why?
|
Diabetes Mellitus, Type 2 | 8 | 2023 | 12076 | 0.180 |
Why?
|
Amygdala | 2 | 2019 | 1351 | 0.180 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1206 | 0.180 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 461 | 0.180 |
Why?
|
Hyperandrogenism | 1 | 2000 | 39 | 0.180 |
Why?
|
Bone and Bones | 6 | 2004 | 2560 | 0.180 |
Why?
|
Receptors, Purinergic P2X5 | 1 | 2019 | 6 | 0.180 |
Why?
|
Pulsatile Flow | 3 | 2011 | 320 | 0.180 |
Why?
|
Pituitary-Adrenal System | 3 | 1999 | 552 | 0.170 |
Why?
|
Dietary Fats | 2 | 2007 | 1991 | 0.170 |
Why?
|
Amino Acid Transport Systems, Neutral | 1 | 2019 | 39 | 0.170 |
Why?
|
HIV Long-Term Survivors | 1 | 2020 | 121 | 0.170 |
Why?
|
Contraceptives, Oral | 1 | 2002 | 554 | 0.170 |
Why?
|
Home Care Services | 1 | 2006 | 647 | 0.170 |
Why?
|
Body Height | 3 | 2010 | 1567 | 0.160 |
Why?
|
Prognosis | 7 | 2024 | 29558 | 0.160 |
Why?
|
Perfusion | 1 | 2023 | 1374 | 0.160 |
Why?
|
Peptides | 3 | 2006 | 4341 | 0.160 |
Why?
|
Serum | 2 | 2019 | 210 | 0.160 |
Why?
|
Caspase 1 | 1 | 2019 | 226 | 0.160 |
Why?
|
Hepatitis | 1 | 2020 | 229 | 0.160 |
Why?
|
Ultrasonography | 5 | 2011 | 5952 | 0.160 |
Why?
|
Blood Chemical Analysis | 2 | 2019 | 437 | 0.150 |
Why?
|
Administration, Cutaneous | 3 | 2009 | 712 | 0.150 |
Why?
|
Drug Resistance, Viral | 1 | 2023 | 860 | 0.150 |
Why?
|
Predictive Value of Tests | 10 | 2019 | 15225 | 0.150 |
Why?
|
Anti-Mullerian Hormone | 1 | 2020 | 407 | 0.150 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2021 | 607 | 0.150 |
Why?
|
Basal Metabolism | 1 | 1998 | 161 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3734 | 0.140 |
Why?
|
Radiopharmaceuticals | 3 | 2017 | 2634 | 0.140 |
Why?
|
Didanosine | 2 | 2007 | 151 | 0.140 |
Why?
|
Technetium Tc 99m Pentetate | 1 | 2017 | 67 | 0.140 |
Why?
|
Diet | 4 | 2022 | 8003 | 0.140 |
Why?
|
Mannans | 1 | 2017 | 58 | 0.140 |
Why?
|
Mannose-Binding Lectins | 1 | 2017 | 96 | 0.140 |
Why?
|
Symporters | 1 | 2019 | 360 | 0.140 |
Why?
|
Natriuretic Peptides | 1 | 2018 | 155 | 0.140 |
Why?
|
Tomography, X-Ray | 1 | 2016 | 60 | 0.140 |
Why?
|
Boston | 8 | 2019 | 9304 | 0.140 |
Why?
|
HIV Seropositivity | 1 | 2002 | 960 | 0.140 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 2211 | 0.140 |
Why?
|
Carrier Proteins | 3 | 2021 | 4937 | 0.140 |
Why?
|
Osteocalcin | 4 | 2006 | 274 | 0.140 |
Why?
|
Comorbidity | 5 | 2020 | 10495 | 0.140 |
Why?
|
Cross-Over Studies | 3 | 2010 | 2048 | 0.140 |
Why?
|
Anabolic Agents | 1 | 1999 | 252 | 0.140 |
Why?
|
Mitochondria | 1 | 2009 | 3584 | 0.130 |
Why?
|
Patient Selection | 2 | 2020 | 4244 | 0.130 |
Why?
|
Phenotype | 4 | 2021 | 16534 | 0.130 |
Why?
|
Depressive Disorder | 2 | 2018 | 3727 | 0.130 |
Why?
|
Thyrotropin | 2 | 2013 | 832 | 0.130 |
Why?
|
Acromegaly | 2 | 1998 | 306 | 0.130 |
Why?
|
T-Lymphocyte Subsets | 1 | 2024 | 1807 | 0.130 |
Why?
|
Fractures, Bone | 1 | 2008 | 2040 | 0.130 |
Why?
|
Gonadal Steroid Hormones | 4 | 2011 | 701 | 0.130 |
Why?
|
Circadian Rhythm | 2 | 2005 | 2567 | 0.130 |
Why?
|
Food Supply | 1 | 2022 | 543 | 0.130 |
Why?
|
Lamivudine | 2 | 2007 | 362 | 0.130 |
Why?
|
Body Constitution | 3 | 2007 | 273 | 0.130 |
Why?
|
Cytoskeletal Proteins | 1 | 2021 | 1342 | 0.130 |
Why?
|
Muscle Cells | 1 | 2016 | 194 | 0.130 |
Why?
|
Particle Size | 2 | 2012 | 1641 | 0.130 |
Why?
|
Radiography, Abdominal | 1 | 2019 | 532 | 0.130 |
Why?
|
Homeostasis | 6 | 2014 | 3302 | 0.130 |
Why?
|
Physical Endurance | 3 | 2013 | 362 | 0.130 |
Why?
|
Zidovudine | 2 | 2007 | 624 | 0.120 |
Why?
|
Paracrine Communication | 1 | 2017 | 276 | 0.120 |
Why?
|
Biopsy | 2 | 2021 | 6768 | 0.120 |
Why?
|
Calcium | 10 | 2014 | 5721 | 0.120 |
Why?
|
Drug Therapy, Combination | 5 | 2011 | 6293 | 0.120 |
Why?
|
Dextrans | 1 | 2017 | 573 | 0.120 |
Why?
|
Phosphorus | 3 | 2007 | 335 | 0.120 |
Why?
|
Gene Silencing | 1 | 2021 | 1507 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 3801 | 0.120 |
Why?
|
Body Size | 3 | 2006 | 462 | 0.120 |
Why?
|
Sodium, Dietary | 1 | 2018 | 425 | 0.120 |
Why?
|
Heart Failure | 1 | 2019 | 11594 | 0.120 |
Why?
|
Disease Progression | 5 | 2021 | 13468 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2012 | 5818 | 0.120 |
Why?
|
Gender Identity | 1 | 2020 | 757 | 0.120 |
Why?
|
Minerals | 1 | 1995 | 283 | 0.120 |
Why?
|
Oxytocin | 1 | 2018 | 401 | 0.120 |
Why?
|
Vasculitis | 2 | 2017 | 522 | 0.110 |
Why?
|
Risk Management | 1 | 2017 | 557 | 0.110 |
Why?
|
Physical Fitness | 2 | 2013 | 732 | 0.110 |
Why?
|
Cosyntropin | 2 | 2005 | 34 | 0.110 |
Why?
|
Puberty | 4 | 2011 | 498 | 0.110 |
Why?
|
Lectins, C-Type | 1 | 2017 | 585 | 0.110 |
Why?
|
Nucleosides | 2 | 2022 | 131 | 0.110 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 2850 | 0.110 |
Why?
|
PPAR gamma | 2 | 2007 | 482 | 0.110 |
Why?
|
Estradiol | 5 | 2005 | 1933 | 0.110 |
Why?
|
Drug Combinations | 3 | 2004 | 2020 | 0.110 |
Why?
|
Adipocytes, Brown | 1 | 2014 | 149 | 0.110 |
Why?
|
Age Factors | 6 | 2020 | 18357 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2023 | 4353 | 0.110 |
Why?
|
Choline | 1 | 2015 | 513 | 0.110 |
Why?
|
Risk | 3 | 2010 | 9599 | 0.110 |
Why?
|
Quality of Life | 8 | 2018 | 13286 | 0.100 |
Why?
|
Adrenal Insufficiency | 1 | 1994 | 194 | 0.100 |
Why?
|
Transcription Factors | 2 | 2019 | 12096 | 0.100 |
Why?
|
Echocardiography, Stress | 1 | 2013 | 134 | 0.100 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 316 | 0.100 |
Why?
|
Osteogenesis | 2 | 1996 | 1271 | 0.100 |
Why?
|
Thinness | 2 | 2008 | 490 | 0.100 |
Why?
|
DNA, Mitochondrial | 2 | 2008 | 856 | 0.100 |
Why?
|
Viral Proteins | 1 | 2019 | 1803 | 0.100 |
Why?
|
Follow-Up Studies | 7 | 2021 | 39060 | 0.100 |
Why?
|
Tomography, Spiral Computed | 1 | 2013 | 273 | 0.100 |
Why?
|
Viscera | 2 | 2003 | 138 | 0.100 |
Why?
|
Time Factors | 12 | 2019 | 39873 | 0.100 |
Why?
|
Spleen | 1 | 2017 | 2296 | 0.090 |
Why?
|
Societies | 2 | 2021 | 108 | 0.090 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2012 | 113 | 0.090 |
Why?
|
Self Report | 1 | 2022 | 3712 | 0.090 |
Why?
|
Fenofibrate | 1 | 2011 | 87 | 0.090 |
Why?
|
RANK Ligand | 1 | 2012 | 318 | 0.090 |
Why?
|
Child Nutrition Disorders | 1 | 2012 | 150 | 0.090 |
Why?
|
Drug Interactions | 1 | 2015 | 1414 | 0.090 |
Why?
|
Linear Models | 4 | 2016 | 5861 | 0.090 |
Why?
|
Mesenchymal Stem Cells | 1 | 2021 | 1634 | 0.090 |
Why?
|
Collagen Type I | 2 | 2006 | 616 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2021 | 2980 | 0.090 |
Why?
|
Niacin | 1 | 2011 | 118 | 0.090 |
Why?
|
Mineralocorticoids | 1 | 2010 | 37 | 0.090 |
Why?
|
Injections, Subcutaneous | 2 | 2006 | 677 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3480 | 0.090 |
Why?
|
Hypertrophy | 1 | 2012 | 555 | 0.090 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2012 | 263 | 0.090 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2011 | 190 | 0.090 |
Why?
|
Hyperemia | 1 | 2011 | 221 | 0.090 |
Why?
|
Osteoblasts | 1 | 1995 | 1142 | 0.090 |
Why?
|
Diet, Reducing | 1 | 2013 | 485 | 0.080 |
Why?
|
Osteopontin | 1 | 2011 | 301 | 0.080 |
Why?
|
Gene Expression Regulation | 3 | 2017 | 11894 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3425 | 0.080 |
Why?
|
Growth | 1 | 2011 | 365 | 0.080 |
Why?
|
Ergolines | 1 | 2009 | 57 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 970 | 0.080 |
Why?
|
Endocrinology | 1 | 2015 | 441 | 0.080 |
Why?
|
Incidence | 7 | 2018 | 21273 | 0.080 |
Why?
|
Cognition | 2 | 2003 | 6955 | 0.080 |
Why?
|
Clinical Laboratory Techniques | 1 | 1994 | 748 | 0.080 |
Why?
|
Ovary | 2 | 2005 | 958 | 0.080 |
Why?
|
Micronutrients | 1 | 2012 | 381 | 0.080 |
Why?
|
Abdomen | 3 | 2005 | 1129 | 0.080 |
Why?
|
Blotting, Western | 2 | 2009 | 5031 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2016 | 2189 | 0.080 |
Why?
|
Benzoxazines | 2 | 2007 | 309 | 0.080 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1557 | 0.080 |
Why?
|
Manometry | 1 | 2011 | 453 | 0.080 |
Why?
|
Dehydroepiandrosterone Sulfate | 2 | 2001 | 240 | 0.080 |
Why?
|
Immunity, Innate | 2 | 2017 | 3046 | 0.080 |
Why?
|
Reproduction | 2 | 2020 | 646 | 0.080 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15785 | 0.080 |
Why?
|
Massachusetts | 4 | 2013 | 8823 | 0.080 |
Why?
|
Mice, Knockout | 2 | 2021 | 14354 | 0.080 |
Why?
|
Animals | 10 | 2021 | 167777 | 0.080 |
Why?
|
Hyperprolactinemia | 1 | 2009 | 123 | 0.080 |
Why?
|
Coronary Stenosis | 2 | 2014 | 793 | 0.080 |
Why?
|
Exercise Test | 2 | 2010 | 2121 | 0.080 |
Why?
|
Interleukin-6 | 3 | 2018 | 3208 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2125 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 2292 | 0.070 |
Why?
|
Patient Participation | 1 | 2017 | 1436 | 0.070 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 2222 | 0.070 |
Why?
|
Tissue Distribution | 1 | 2012 | 2263 | 0.070 |
Why?
|
Ritonavir | 1 | 2009 | 328 | 0.070 |
Why?
|
Heart Valves | 1 | 2009 | 284 | 0.070 |
Why?
|
Pituitary Neoplasms | 2 | 2013 | 1313 | 0.070 |
Why?
|
Glycemic Index | 1 | 2009 | 393 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2020 | 58681 | 0.070 |
Why?
|
Luteinizing Hormone | 2 | 2011 | 820 | 0.070 |
Why?
|
Flow Cytometry | 2 | 2021 | 5864 | 0.070 |
Why?
|
Atrophy | 1 | 2012 | 1627 | 0.070 |
Why?
|
Pyrimidinones | 1 | 2009 | 383 | 0.070 |
Why?
|
Hemochromatosis | 1 | 2008 | 174 | 0.070 |
Why?
|
Malnutrition | 2 | 2022 | 639 | 0.070 |
Why?
|
Sex Hormone-Binding Globulin | 2 | 2000 | 546 | 0.070 |
Why?
|
Cortodoxone | 1 | 2005 | 17 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2239 | 0.070 |
Why?
|
Cell Differentiation | 2 | 2021 | 11471 | 0.070 |
Why?
|
Contraceptives, Oral, Synthetic | 1 | 2005 | 16 | 0.070 |
Why?
|
Androstenedione | 1 | 2005 | 131 | 0.060 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2009 | 357 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2017 | 3485 | 0.060 |
Why?
|
Pregnancy | 3 | 2023 | 29742 | 0.060 |
Why?
|
Trace Elements | 2 | 2012 | 196 | 0.060 |
Why?
|
Calcifediol | 1 | 2006 | 161 | 0.060 |
Why?
|
Electric Impedance | 2 | 2000 | 754 | 0.060 |
Why?
|
Hemodynamics | 2 | 2006 | 4159 | 0.060 |
Why?
|
Metabolome | 1 | 2012 | 982 | 0.060 |
Why?
|
Thorax | 2 | 2005 | 553 | 0.060 |
Why?
|
Stroke | 3 | 2018 | 9696 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3671 | 0.060 |
Why?
|
Health Promotion | 1 | 2017 | 2202 | 0.060 |
Why?
|
Petrosal Sinus Sampling | 1 | 2004 | 22 | 0.060 |
Why?
|
Child | 12 | 2023 | 79813 | 0.060 |
Why?
|
Glucose Transporter Type 4 | 1 | 2005 | 240 | 0.060 |
Why?
|
Etidronic Acid | 1 | 2004 | 63 | 0.060 |
Why?
|
Dehydroepiandrosterone | 1 | 2005 | 257 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2020 | 4313 | 0.060 |
Why?
|
Femur Neck | 1 | 2006 | 312 | 0.060 |
Why?
|
Blood Cell Count | 1 | 2005 | 395 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 6154 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2016 | 2049 | 0.060 |
Why?
|
Follicle Stimulating Hormone | 1 | 2006 | 725 | 0.060 |
Why?
|
Least-Squares Analysis | 1 | 2004 | 369 | 0.060 |
Why?
|
Oligopeptides | 1 | 2009 | 1185 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2476 | 0.060 |
Why?
|
Subcutaneous Tissue | 1 | 2004 | 132 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2019 | 4457 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2006 | 10747 | 0.060 |
Why?
|
Logistic Models | 2 | 2009 | 13276 | 0.050 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2005 | 436 | 0.050 |
Why?
|
Oxazines | 1 | 2005 | 341 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3526 | 0.050 |
Why?
|
Signal Transduction | 2 | 2018 | 23341 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2014 | 7377 | 0.050 |
Why?
|
Mice | 6 | 2021 | 81107 | 0.050 |
Why?
|
Cerebral Hemorrhage | 1 | 2014 | 2650 | 0.050 |
Why?
|
Femur | 2 | 2006 | 1302 | 0.050 |
Why?
|
Thyroid Diseases | 2 | 1998 | 386 | 0.050 |
Why?
|
Thigh | 1 | 2004 | 240 | 0.050 |
Why?
|
Pandemics | 1 | 2023 | 8611 | 0.050 |
Why?
|
P-Selectin | 1 | 2005 | 597 | 0.050 |
Why?
|
Hunger | 1 | 2004 | 206 | 0.050 |
Why?
|
Feedback, Physiological | 1 | 2005 | 475 | 0.050 |
Why?
|
Appetite Regulation | 1 | 2003 | 84 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2019 | 7843 | 0.050 |
Why?
|
Platelet Count | 1 | 2005 | 775 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2011 | 1704 | 0.050 |
Why?
|
Fatty Acids | 2 | 2003 | 1803 | 0.050 |
Why?
|
Epidemiologic Methods | 1 | 2007 | 1338 | 0.050 |
Why?
|
Intelligence Tests | 1 | 2003 | 500 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9575 | 0.050 |
Why?
|
Patient Compliance | 3 | 2018 | 2685 | 0.050 |
Why?
|
Retrospective Studies | 11 | 2021 | 80170 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2004 | 403 | 0.050 |
Why?
|
Hawaii | 1 | 2021 | 101 | 0.050 |
Why?
|
Protons | 1 | 2007 | 1112 | 0.050 |
Why?
|
Pilot Projects | 4 | 2011 | 8554 | 0.050 |
Why?
|
Affect | 1 | 2009 | 1480 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2005 | 791 | 0.050 |
Why?
|
Contrast Media | 1 | 2014 | 5298 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2882 | 0.050 |
Why?
|
Appetite | 1 | 2023 | 247 | 0.050 |
Why?
|
Motor Activity | 1 | 2010 | 2686 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2010 | 2144 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 114 | 0.050 |
Why?
|
Skinfold Thickness | 1 | 2000 | 158 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2270 | 0.050 |
Why?
|
Scintillation Counting | 1 | 2000 | 36 | 0.040 |
Why?
|
Prednisone | 1 | 2005 | 1565 | 0.040 |
Why?
|
North America | 1 | 2024 | 1276 | 0.040 |
Why?
|
Educational Status | 1 | 2008 | 2513 | 0.040 |
Why?
|
Neurobiology | 1 | 2021 | 137 | 0.040 |
Why?
|
Follicular Phase | 1 | 2000 | 143 | 0.040 |
Why?
|
Integrases | 1 | 2022 | 516 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2006 | 1846 | 0.040 |
Why?
|
Wasting Syndrome | 1 | 2000 | 97 | 0.040 |
Why?
|
California | 1 | 2024 | 1419 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2021 | 468 | 0.040 |
Why?
|
Recovery of Function | 1 | 2010 | 2971 | 0.040 |
Why?
|
Electrocardiography | 1 | 2013 | 6363 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2005 | 1150 | 0.040 |
Why?
|
Lipoproteins | 2 | 2002 | 881 | 0.040 |
Why?
|
Nandrolone | 1 | 1999 | 17 | 0.040 |
Why?
|
Oxandrolone | 1 | 1999 | 24 | 0.040 |
Why?
|
Chorionic Gonadotropin | 1 | 2001 | 457 | 0.040 |
Why?
|
Arteries | 1 | 2024 | 1125 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2000 | 553 | 0.040 |
Why?
|
Nutritional Requirements | 1 | 2000 | 275 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 1995 | 1797 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4839 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2011 | 5098 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9405 | 0.040 |
Why?
|
Acute Disease | 1 | 2009 | 7225 | 0.040 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2004 | 617 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2021 | 655 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2021 | 559 | 0.040 |
Why?
|
Osteoprotegerin | 2 | 2012 | 176 | 0.040 |
Why?
|
Research Personnel | 1 | 2023 | 582 | 0.040 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2017 | 38 | 0.040 |
Why?
|
Steroids | 1 | 2003 | 926 | 0.040 |
Why?
|
Menarche | 1 | 2000 | 529 | 0.040 |
Why?
|
Registries | 2 | 2017 | 8176 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2019 | 250 | 0.040 |
Why?
|
Ovulation | 1 | 1998 | 181 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2860 | 0.040 |
Why?
|
Arm | 1 | 2000 | 583 | 0.040 |
Why?
|
gamma-Glutamyltransferase | 1 | 2017 | 144 | 0.040 |
Why?
|
Dietary Supplements | 2 | 2001 | 3388 | 0.040 |
Why?
|
Hip Joint | 1 | 2004 | 1007 | 0.040 |
Why?
|
Radioimmunoassay | 1 | 1997 | 866 | 0.040 |
Why?
|
Megestrol Acetate | 1 | 1996 | 18 | 0.040 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2004 | 1489 | 0.040 |
Why?
|
Receptors, Interleukin-1 | 1 | 2018 | 261 | 0.040 |
Why?
|
Mass Screening | 1 | 2013 | 5425 | 0.040 |
Why?
|
Electrolytes | 1 | 1998 | 274 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1263 | 0.040 |
Why?
|
Outpatients | 1 | 2005 | 1591 | 0.030 |
Why?
|
Rupture, Spontaneous | 1 | 2017 | 353 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2022 | 799 | 0.030 |
Why?
|
Tissue Plasminogen Activator | 1 | 2002 | 1156 | 0.030 |
Why?
|
Uganda | 1 | 2021 | 1324 | 0.030 |
Why?
|
Algorithms | 2 | 2010 | 13959 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2012 | 10417 | 0.030 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2018 | 195 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 12440 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2005 | 1660 | 0.030 |
Why?
|
Transsexualism | 1 | 2020 | 206 | 0.030 |
Why?
|
Galectin 3 | 1 | 2018 | 240 | 0.030 |
Why?
|
Body Fluids | 1 | 1998 | 319 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2004 | 2509 | 0.030 |
Why?
|
Alkynes | 2 | 2007 | 312 | 0.030 |
Why?
|
Glycoproteins | 1 | 2003 | 2205 | 0.030 |
Why?
|
History, 21st Century | 1 | 2022 | 1573 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36285 | 0.030 |
Why?
|
Musculoskeletal Physiological Phenomena | 1 | 2015 | 30 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6955 | 0.030 |
Why?
|
Leg | 1 | 2000 | 1087 | 0.030 |
Why?
|
Galectins | 1 | 2018 | 282 | 0.030 |
Why?
|
Syndrome | 1 | 2001 | 3262 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2097 | 0.030 |
Why?
|
Cyclopropanes | 2 | 2007 | 431 | 0.030 |
Why?
|
Acid-Base Equilibrium | 1 | 1995 | 180 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6493 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2005 | 3709 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2014 | 5331 | 0.030 |
Why?
|
Nutrition Policy | 1 | 2019 | 470 | 0.030 |
Why?
|
Diet Surveys | 1 | 2019 | 1161 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2017 | 514 | 0.030 |
Why?
|
Parenteral Nutrition | 1 | 1999 | 656 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2007 | 14641 | 0.030 |
Why?
|
Premenopause | 1 | 1998 | 1038 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2004 | 8530 | 0.030 |
Why?
|
Thalidomide | 1 | 1999 | 884 | 0.030 |
Why?
|
Image Enhancement | 1 | 2004 | 2880 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1999 | 733 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2019 | 1436 | 0.030 |
Why?
|
Water-Electrolyte Balance | 1 | 1994 | 325 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1430 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2007 | 7817 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2019 | 3593 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2111 | 0.030 |
Why?
|
Forecasting | 1 | 2002 | 2920 | 0.030 |
Why?
|
Women's Health | 1 | 2003 | 2057 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2084 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2008 | 4317 | 0.030 |
Why?
|
Collagen | 1 | 2001 | 2635 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2017 | 1527 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 1997 | 2210 | 0.030 |
Why?
|
Societies, Medical | 1 | 2005 | 3891 | 0.030 |
Why?
|
Isoleucine | 1 | 2012 | 110 | 0.030 |
Why?
|
Vitamins | 1 | 2001 | 1632 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2016 | 1539 | 0.030 |
Why?
|
Exosomes | 1 | 2017 | 423 | 0.030 |
Why?
|
Organ Specificity | 1 | 2017 | 1955 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12951 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2008 | 15773 | 0.020 |
Why?
|
Osteoclasts | 1 | 1995 | 710 | 0.020 |
Why?
|
Community Health Services | 1 | 2017 | 655 | 0.020 |
Why?
|
Follicle Stimulating Hormone, Human | 1 | 2011 | 25 | 0.020 |
Why?
|
Single-Blind Method | 1 | 1995 | 1570 | 0.020 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2014 | 414 | 0.020 |
Why?
|
Testis | 1 | 1994 | 794 | 0.020 |
Why?
|
Leucine | 1 | 2012 | 547 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1871 | 0.020 |
Why?
|
Hypertension | 1 | 2011 | 8503 | 0.020 |
Why?
|
Valine | 1 | 2012 | 408 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17768 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2000 | 2690 | 0.020 |
Why?
|
Drug Resistance | 1 | 1996 | 1593 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2020 | 2058 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 698 | 0.020 |
Why?
|
Kidney | 2 | 1995 | 7016 | 0.020 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2013 | 540 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2000 | 6013 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 965 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2015 | 830 | 0.020 |
Why?
|
Hospitals, General | 1 | 2013 | 795 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2014 | 892 | 0.020 |
Why?
|
Hormone Antagonists | 1 | 2009 | 108 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20052 | 0.020 |
Why?
|
Ascorbic Acid | 1 | 2012 | 655 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3846 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2001 | 4020 | 0.020 |
Why?
|
Prolactinoma | 1 | 2009 | 113 | 0.020 |
Why?
|
Sequence Analysis | 1 | 2008 | 240 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1973 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18125 | 0.020 |
Why?
|
Skin | 1 | 2001 | 4464 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4069 | 0.020 |
Why?
|
Prolactin | 1 | 2009 | 621 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6821 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2019 | 9518 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2017 | 2307 | 0.020 |
Why?
|
Tanzania | 1 | 2011 | 1383 | 0.020 |
Why?
|
Spine | 2 | 2006 | 1111 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 1722 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 1998 | 3446 | 0.020 |
Why?
|
Receptors, HIV | 1 | 2006 | 159 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2011 | 1986 | 0.020 |
Why?
|
Child, Preschool | 2 | 2009 | 42058 | 0.020 |
Why?
|
Differential Threshold | 1 | 2004 | 80 | 0.010 |
Why?
|
Brain Ischemia | 1 | 2017 | 3047 | 0.010 |
Why?
|
Genotype | 2 | 2008 | 12945 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26182 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7590 | 0.010 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 2004 | 361 | 0.010 |
Why?
|
Bilirubin | 1 | 2003 | 437 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 18942 | 0.010 |
Why?
|
Vitamin D | 1 | 1995 | 3283 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2008 | 2697 | 0.010 |
Why?
|
Infant | 1 | 2023 | 36054 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7985 | 0.010 |
Why?
|
Models, Biological | 1 | 2017 | 9461 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5484 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2006 | 1826 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2006 | 1888 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4567 | 0.010 |
Why?
|
Phosphates | 1 | 2002 | 771 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 283 | 0.010 |
Why?
|
Interleukin-1 | 1 | 2002 | 1249 | 0.010 |
Why?
|
Organ Size | 1 | 2003 | 2252 | 0.010 |
Why?
|
Hip Fractures | 1 | 2006 | 987 | 0.010 |
Why?
|
Rest | 1 | 2002 | 914 | 0.010 |
Why?
|
Lactic Acid | 1 | 2002 | 1133 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 1999 | 865 | 0.010 |
Why?
|
ROC Curve | 1 | 2004 | 3563 | 0.010 |
Why?
|
Recurrence | 2 | 1999 | 8426 | 0.010 |
Why?
|
Echocardiography | 1 | 2009 | 4962 | 0.010 |
Why?
|
Lipoprotein(a) | 1 | 2000 | 479 | 0.010 |
Why?
|
Morbidity | 1 | 1998 | 1754 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1999 | 2359 | 0.010 |
Why?
|
Psychotherapy | 1 | 1999 | 1640 | 0.010 |
Why?
|
Disabled Persons | 1 | 1998 | 1224 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2009 | 13591 | 0.000 |
Why?
|
Survival Rate | 1 | 1999 | 12721 | 0.000 |
Why?
|
Chronic Disease | 1 | 1998 | 9266 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1998 | 15638 | 0.000 |
Why?
|